Abstract
One of the major failures in the treatment of acute lymphoblastic leukemia (ALL) is the relapse process, in which leukemic cells resistant to chemotherapy do not respond to treatment. Currently, new therapeutic approaches have been incorporated into leukemia treatments, contributing to significant progress in the outcome of these malignancies. Targeted therapies, such as the use of monocl…